

## **Identification of the putative causal risk factors and biomarkers of stroke using large-scale genome-wide studies**

Tania Islam<sup>1</sup>, Luis M García-Marín<sup>2,3</sup>, Miguel E. Rentería<sup>2,3</sup>, Gabriel Cuellar-Partida<sup>4</sup>, Asaduzzaman Khan<sup>1</sup>, Mohammad Ali Moni<sup>1,\*</sup>

<sup>1</sup> School of Health and Rehabilitation Sciences, Faculty of Health, The University of Queensland, Brisbane, QLD 4072, Australia

<sup>2</sup>Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

<sup>3</sup>School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia

<sup>4</sup>Diamantina Institute, The University of Queensland & Translational Research Institute, Woolloongabba QLD, Australia

### **\*Corresponding author:**

Dr. Mohammad Ali Moni  
School of Health and Rehabilitation Sciences,  
Faculty of Health, The University of Queensland,  
Brisbane, QLD 4072, Australia  
E-mail: m.moni@uq.edu.au

1 **Abstract**

2 Stroke is a complex neurological disorder, and the risk factors and genetic biomarkers  
3 associated with stroke development are not completely understood. This study aims to identify  
4 putative causal traits and their biomarkers that influence the risk of stroke. Here the latent  
5 causal variable (LCV) method has been used to investigate the potential causal genetic  
6 relationships between large-scale genome-wide association studies (GWAS) data of 1504  
7 complex traits from UK Biobank and stroke. Generalised Mendelian randomisation (GSMR)  
8 method has also been further used to examine causal inference. These analyses suggest 14  
9 causal traits associated with stroke risk ( $|GCP| > 0.60$ ;  $FDR < 0.05$ ), including atrial fibrillation,  
10 deep venous thrombosis, gamma-glutamyl transferase, and platelet crit. Gene-based analysis  
11 has revealed shared genes, providing novel insights into the genetic biomarkers of the causal  
12 traits on stroke risk. Functional enrichment analyses of the shared genes have provided  
13 biological pathways underlying biological mechanisms to stroke risk, including “oxidative  
14 damage”, “platelet activation”, “cell aging”, and others. This study provides causal evidence  
15 of cardiovascular, metabolic, and blood clot-related traits increasing stroke risk. The identified  
16 shared gene biomarkers provide valuable insights into the shared genetic biomarkers and  
17 underlying mechanisms linking causal traits to stroke risk.

18

19 **Keywords:** Stroke, latent causal variable method, summary statistic for complex traits, and  
20 genome-wide association studies (GWAS).

21

22

23

24

25

## 1 **Introduction**

2 Stroke is the second largest cause of mortality and disability worldwide [1]. Stroke affects  
3 around 13.7 million individuals, and about 5.5 million die yearly [2]. Stroke is a neurological  
4 condition characterised by blockage of a blood vessel. For instance, blood clots can form in the  
5 brain, obstructing blood flow and causing blood vessels to rupture, resulting in haemorrhage in  
6 the brain. When the brain arteries rupture during a stroke event, the lack of oxygen causes the  
7 brain cells to die[2].

8 Clinical and epidemiological studies have repeatedly discovered a hereditary component to  
9 stroke vulnerability along with more typical risk factors, including smoking, hypertension, and  
10 diabetes mellitus [3]. Twins' studies and family history also provide evidence that genetic  
11 susceptibility is significant in stroke aetiology [4]. The estimated heritability was 37.9% for all  
12 ischemic strokes [5]. In genome-wide association studies (GWAS), several significant risk loci  
13 have been identified as associated with stroke [6]. For instance, cardioembolic stroke was  
14 linked to two atrial fibrillation-related loci (*PITX2* and *ZFHX3*), whereas large-vessel stroke  
15 was linked to a locus on chromosome 9p21 that was previously associated with coronary artery  
16 disease [7]. In addition, a multi-ancestry GWAS analysis revealed 35 risk loci associated with  
17 the aetiology of stroke and its subtypes [8,9]. Recently, cross-ancestry meta-analyses of GWAS  
18 summary data on stroke identified a total of 89 independent loci significantly associated with  
19 stroke and stroke subtypes [10]. Mendelian randomisation (MR) was used genetic data to  
20 understand the causal role of traits on stroke risk [11]. For example, blood pressure, atrial  
21 fibrillation, venous thrombosis, circulating lipoproteins, LDL (low-density lipoprotein)  
22 cholesterol, obesity, type 2 diabetes, insulin resistance, hyperglycaemia, education, BMI,  
23 physical activity, alcohol consumption and smoking have been associated with increased risk  
24 of stroke using MR [11,12]. Mendelian randomisation (MR) and latent causal variable (LCV)  
25 approaches examine the influence of genetic liability for a specific trait on the outcome [13,14].

1 Interestingly, the LCV method represents some advantages over MR methods. Firstly, in  
2 contrast to conventional MR methods, LCV can accurately differentiate between genetic  
3 correlation and full or partial genetic causality. In addition, positive LCV outcomes are more  
4 likely to represent actual causal effects. Secondly, the genetic causality proportion (*gcp-value*)  
5 can be easily estimated by quantifying the degree of causation, while MR methods, especially  
6 MR Egger can be easily confounded by genetic correlations [15]. In addition, the instrumental  
7 variables defined by the conventional MR method may exhibit putative pleiotropic effect (SNP  
8 instruments have an impact on both risk factors and diseases), which may violate the MR  
9 method assumption. The recently developed generalised summary data-based Mendelian  
10 randomisation (GSMR) approach uses more SNPs as instrumental variables and has a strong  
11 statistical power than the conventional MR approach. Furthermore, the GSMR approach used  
12 the HEIDI outlier method, which eliminates pleiotropic outliers, therefore GSMR results were  
13 not influenced by the pleiotropic effect of risk factors and disease and offered unbiased  
14 estimates of the causal influence.

15 A genetic correlation might be explained by pleiotropic effects, which can be vertical or  
16 horizontal [16]. When genetic variants directly influence trait A and trait B, this type of effect  
17 is called horizontal pleiotropy. On the other hand, vertical pleiotropy may be seen as a causal  
18 cascade where the influence of a genetic variant on a single trait is explained by its impact on  
19 another trait [13]. Horizontal pleiotropy could lead to high-false positive results in genetic  
20 epidemiology to assess the causality [15,17].

21 Due to the massive public health concerns with severe socio-economic consequences, there is  
22 a growing interest in exploring the potential causal genetic risk factors of stroke. Therefore, in  
23 the present study, we perform a hypothesis-free exploratory large-scale genetic screening for  
24 risk factors of stroke using the LCV method, which is less susceptible to confounding by  
25 horizontal pleiotropic effects [15]. Our findings support some of the causal associations

1 hypothesised by observational studies and shed light on the relationship between stroke,  
2 lifestyle factors, diseases, and health conditions. Finally, we performed gene-based and  
3 pathway-based analyses to discover shared gene biomarkers and underlying pathways for the  
4 causal traits and stroke.

5

## 6 **Materials and Methods**

7 The overall analytical approach that we employed in this study is shown in Figure 1.

### 8 **Stroke data**

9 We obtained GWAS summary statistics for stroke from a meta-analysis of GWAS data from  
10 MEGASTROKE consortium (<http://megastroke.org/>). This data is generated based on the  
11 fixed-effects meta-analysis of GWAS in 40,585 stroke cases and 406,111 controls of European  
12 ancestry. The details of the study have been described in [18].

13

### 14 **UK biobank cohort datasets**

15 We used 1504 phenotypes available at the Complex Traits Genetics Virtual Lab (CTG-VL)  
16 web-portal (<https://genoma.io>) [19], which is generated based on UK Biobank datasets  
17 (<http://www.nealelab.is/uk-biobank>). As a result, the majority of these GWAS summary results  
18 represent people of European ancestry, which eliminates potential biases due to genetic  
19 ancestry variations. This data was corrected for age, age-squared, inferred sex and genetic  
20 ancestry [19].

21

### 22 **Latent causal variable**

23 The latent causal variable (LCV) is a model used to assess the causal association of two  
24 genetically correlated traits. LCV considers a latent variable (L) that has a causal effect on each  
25 trait [15]. The GCP value indicates if the genetic correlation is due mainly to horizontal or

1 vertical pleiotropy and is calculated by determining the correlations between latent variable L  
2 with trait A and trait B respectively [15]. A GCP value of 0 indicates that the genetic correlation  
3 is mediated by horizontal pleiotropic effects, suggesting the absence of causal genetic effects.  
4 On the other hand,  $|GCP| = 1$  denotes the presence of vertical pleiotropic effects as well as  
5 complete genetic causality. A  $|GCP| > 0.6$  is regarded as a robust indicator of potential vertical  
6 pleiotropic effects [15]. To evaluate LCV outcomes, three things must be considered: the  
7 amount of genetic correlation, the magnitude of the GCP estimation, and the directionality of  
8 the GCP estimate. The GCP value does not represent the magnitude of prospective causal  
9 effects; rather, it represents the proportion of a genetic correlation that could be described by  
10 potential causal effects. For example, associations with a low genetic correlation ( $|rG| < 0.30$ )  
11 and a high  $|GCP|$  value near 1 indicate that all the genetic elements overlap between two traits,  
12 despite its small genetic correlation, which is likely due to vertical pleiotropic effects.  
13 Furthermore, a negative GCP value between stroke and trait A indicates that trait A may have  
14 causal genetic effects on stroke, whereas a positive GCP value between stroke and trait A  
15 indicates that stroke may have causal genetic effects on trait A.

16 The phenome-wide analytic framework was built by using an R script for the LCV approach  
17 that the original authors of the method made accessible on GitHub [15]. We uploaded GWAS  
18 summary statistics for stroke to perform the analysis on the CTG-VL web platform. The  
19 phenome-wide analytic pipeline was then utilised to perform LD score regression[20] and LCV  
20 analyses[15] to assess genetic correlations and potential putative causal links, respectively. Full  
21 instructions for utilising and understanding the publicly accessible phenome-wide analysis  
22 methodology can be found elsewhere [21]. The LCV was performed on all traits that showed  
23 a genetic correlation with stroke (false discovery rate,  $FDR < 0.05$ ). Similarly, we considered  
24 all GCP estimate values that were significant after multiple testing corrections ( $FDR < 0.05$ ).

25

## 1 **Mendelian Randomization Analysis**

2 To validate the findings of LCV analyses, we performed generalised Mendelian randomisation  
3 (GSMR) analyses. Mendelian randomisation method uses genetic variants (SNPs) as  
4 instrumental variables to identify causal relationships between exposure and outcome [22].  
5 GSMR method uses all the top associated genome-wide significant level SNPs as an  
6 instrumental variable for the exposures to examine the causality [23]. GSMR analysis results  
7 are not influenced by the risk factors and disease. In short, GSMR used the MR framework to  
8 perform summary-based Mendelian randomisation (SMR) analysis on each individual SNP  
9 instrument. This analysis considered the variability in sampling for each SNP and the linkage  
10 disequilibrium (LD) between SNPs. It then combined the causal estimates from all SNP  
11 instruments using generalised least squares method. GSMR estimates the causal relationship  
12 between causal traits (exposure) and stroke (outcome). Additionally, GSMR method employed  
13 HEIDI outlier method ( $p$ -value < 0.01) to exclude the putative pleiotropic outlier SNPs and  
14 unbiasedly, estimates the causal effect of exposures on outcomes [23].

## 15 **Gene-based association analysis**

16 We used fastBAT – a fast set-based association analysis method to identify potential causal  
17 genes. The fastBAT method uses GWAS summary statistics and linkage-disequilibrium  
18 reference to summarise genetic associations with a trait of interest at the gene level [24]. We  
19 performed fastBAT analysis for stroke, atrial fibrillation, self-reported pulmonary embolism,  
20 blood clot in the lung, cardiac arrhythmias, blood clot in the leg diagnosed, medication:  
21 Gliclazide, insulin and piolitzone, deep venous thrombosis, atrial fibrillation and flutter  
22 (ICD10), deep venous thrombosis of lower extremities and pulmonary embolism, platelet crit  
23 and gamma-glutamyl transferase to identify potential causal disease associated genes. The  
24 fastBAT method found the association between 24273 genes. We then adjusted the  $P$ -value

1 using Benjamini-Hochberg method (Adjusted  $p$ -value  $> 0.05$ ) for all traits to identify shared  
2 genes between causal traits and stroke.

3

#### 4 **Functional enrichment analysis of shared genes between complex traits and stroke**

5 We performed functional enrichment analysis of shared genes of the causal traits (i.e.,  
6 cardiovascular traits, blood clot traits (blood in lung, blood clot in leg, DVT, pulmonary  
7 embolism), metabolic traits (gamma glutamyl-transferase), blood trait (platelet crit)) and stroke  
8 using ConsensusPathDB bioinformatics tool [25], accessed on 20 July 2023, for identification  
9 of significant molecular pathways, gene ontology such as biological processes and molecular  
10 functions. ConsensusPathDB is the largest repository for functional enrichment analysis of  
11 genes. We performed pathway enrichment analyses of the shared genes using database for  
12 pathways such as KEGG, BioCarta, Reactome and, Wikipathways. We also performed gene  
13 ontology (GO) enrichment analysis. In the enrichment analysis, the  $p$ -value generated from the  
14 hypergeometric test was adjusted for multiple testing corrections. We considered the  
15 significant pathways and GO terms which passed the adjusted  $p$ -value  $< 0.05$ .

16

## 17 **Results**

### 18 **Identification of causal traits associated with the risk of stroke using latent causal variable** 19 **method**

20 In order to identify potential causal traits of stroke, we have performed phenome-wide  
21 screening using latent causal variable (LCV) analysis by leveraging 1,504 complex traits  
22 GWAS datasets from UK biobank and stroke GWAS from MEGASTROKE consortium. Of  
23 the 1,504 complex traits, we identified 262 traits genetically correlated with stroke risk  
24 (FDR $<0.05$ ; Supplementary Table (S1). Among those genetically correlated traits, 14 could be



1 explained via robust vertical pleiotropic effects with stroke ( $|GCP| > 0.60$ ; FDR  $< 0.05$ ), while  
2 seven showed limited partial genetic causality ( $|GCP| < 0.60$ ; FDR  $< 5\%$ ; (Supplementary Table  
3 S2 & S3 respectively).

4  
5 We observed the putative causal risk factors of stroke including, cardiovascular traits (atrial  
6 fibrillation, cardiac arrhythmias), blood cell trait (platelet crit), liver enzymes (gamma-glutamyl  
7 transferase), physical health conditions such as pulmonary embolism, blood clot in the lung,  
8 blood clot in the leg, deep venous thrombosis of lower extremities. Our findings suggest that  
9 these traits may be causally associated with the risk of stroke (Table 1).

10  
11

## 12 **Exploring the relationships between causal traits and stroke using generalised summary-** 13 **based Mendelian randomisation**

14

15 To further validate the causal relationships identified by LCV method, we performed  
16 generalised summary-based Mendelian randomisation (GSMR) analysis of the causal traits. To  
17 assess causal roles, the causal traits were considered as exposure and stroke was considered as  
18 outcome in GSMR analysis. GSMR analysis showed that putative risk factors suggested by the  
19 LCV method were also consistently causal for stroke. The GSMR suggested cardiovascular  
20 traits (atrial fibrillation, cardiac arrhythmias), physical health conditions (pulmonary embolism,  
21 blood clot in the lung, blood clot in the leg, deep venous thrombosis of lower extremities),  
22 blood cell traits (platelet crit) and liver enzyme (gamma-glutamyl transferase) were found  
23 causally associated with the increase the risk of stroke (Table 2). Due to small sample size,  
24 GSMR could not be performed on the traits, weight change during the worst episode of  
25 depression, and diabetes proxy trait (use of pioglitazone medication).

26

## 27 **Gene-based association analysis of causal traits and stroke**

28

29 To identify genes associated with causal traits and stroke, we performed fastBAT analysis and  
30 identified 97 genes for atrial fibrillation, 202 genes for atrial fibrillation and flutter, 85 genes

1 for blood clot in leg, 58 genes for blood clot in lung, 180 genes for cardiac arrhythmias, 118  
2 genes for DVT of lower extremities and pulmonary embolism, 52 genes for pulmonary  
3 embolism, 10515 gene for platelet crit, 12734 genes for gamma-glutamyl transferase, 85 genes  
4 for stroke (*adjusted p-value* <0.05) (Supplementary Table S4 to S12). Next, Venn analysis  
5 demonstrated several overlapping genes between causal traits and stroke Figure 3 and  
6 (Supplementary Table S13). We found 4 genes (*ZFHX3*, *HCCAT5*, *OBFC1*, *SH3PXD2A*) were  
7 shared among atrial fibrillation, cardiac arrhythmias and stroke. *FGA*, *FGG*, *ILF3*, *FGB*, *ILF3-*  
8 *ASI*, *SH2B3*, *PLRG1*, *ARHGAP1* were overlapped in blood clot in leg, deep venous thrombosis  
9 in lower extremities & pulmonary embolism and stroke. *ARMS2*, *ACAD10*, *CDKN2B-ASI*,  
10 *FOXF2*, *ZFHX3*, among other genes, were shared between DVT and stroke Figure 3 and  
11 (Supplementary Table S13).

12

### 13 **Functional enrichment analysis**

14 To gain a better understanding of the potential biological functions and molecular pathways  
15 that underlie shared genetic overlap between causal traits and stroke, we performed functional  
16 enrichment analysis of those shared candidate genes. Our functional enrichment analysis  
17 revealed some important pathways and gene ontology terms shared between causal traits and  
18 stroke. We found some significant pathways, such as “intrinsic and extrinsic prothrombin  
19 activation pathway”, “fibrinolysis pathway” and “invadopodia formation” pathways were  
20 shared between atrial fibrillation, cardiac arrhythmias, and stroke (Figure 4(A)). In addition,  
21 we also found “blood clotting cascade”, “platelet aggregation”, “fibrin clot formation”,  
22 “regulation of TLR by endogenous ligand” pathways were shared between traits i.e., blood clot  
23 in lung, blood clot in leg, deep venous thrombosis, pulmonary embolism, and stroke (Figure  
24 4(B)). Furthermore, we also found “STAT5 activation downstream of FLT3ITD mutants”,  
25 “FLT3 signalling in disease”, “oxidative damage” and among other pathways were shared  
26 between platelet crit and stroke (Figure 4(C)), and “chronic myeloid leukemia”, “glioma” and

1 “nervous system development pathways were shared by gamma glutamyl-transferase and  
2 stroke (Figure 4(D)) (Supplementary Table S14 to S22).

3  
4 The shared genes were also enriched in some gene ontology pathways, particularly involved in  
5 biological process and molecular functions. We identified some significant GO terms such as  
6 “blood coagulation, fibrin clot formation”, “apoptotic signalling pathway”, “defence response”  
7 were shared by pulmonary embolism and stroke. Furthermore, we also found “cell aging”,  
8 “regulation of cell adhesion” and “regulation of haemostasis” were shared between deep  
9 venous thrombosis and stroke. The enriched gene ontology terms are presented in Figure 5(A-  
10 F).

11  
12

### 13 **Discussion**

14 This study advances our understanding of stroke aetiology by shedding light on the causal  
15 architecture of stroke. We leveraged GWAS summary data to examine the potential causal  
16 association between 1,504 complex traits and stroke. Based on genetic evidence, we discovered  
17 14 traits potentially causally associated with stroke. Consistent with the LCV results, GSMR  
18 analyses also provided significant evidence for the causal genetic influence of those causal  
19 traits in increasing the risk of stroke. Our findings suggest that certain cardiovascular traits,  
20 pathophysiological conditions, vascular disorders, liver enzymes (gamma glutamyl-  
21 transferase), and blood cell traits (platelet crit) may increase the risk of stroke. Furthermore,  
22 gene-based and pathway-based analyses revealed their shared genes and underlying biological  
23 pathways between causal traits and stroke, which may suggest novel molecular insights into  
24 stroke aetiology.

1 Our study revealed that the causal genetic effects of certain traits may influence the risk of  
2 stroke, such as atrial fibrillation (AF). Previous studies reported that AF contributes to the  
3 pathogenesis of stroke by causing stasis in the left atrium and subsequent brain embolism [26].  
4 A study showed that about 15–38% of people who suffered an ischemic stroke had AF [27],  
5 and it also enhanced stroke risk five-fold compared with healthy people [28]. However, apart  
6 from triggering stroke, AF may be associated with other risk factors that may influence stroke.  
7 For instance, age, sex, coronary artery disease, high blood pressure, diabetes, inflammatory  
8 disorders, and cardiac embolism are all potential risk factors for both stroke and AF [29]. Our  
9 study highlighted that the genetic predisposition of AF contributes to stroke risk. Venous  
10 thromboembolism (VTE), also known as deep vein thrombosis (DVT) and pulmonary  
11 embolism (PE), may have a role in circulatory collapse and short- and long-term serious effects  
12 on quality of life [30]. VTE is a complex disorder, with increasing age and obesity recognised  
13 as prevalent atherosclerotic risk factors for ischemic stroke [31]. The incidence of DVT is  
14 higher in aged people with age  $\geq$  65 years [32]. DVT happens when a thrombus (blood clot)  
15 forms in the deep veins, particularly in the lower extremities (legs), which leads to pain,  
16 cramping, and swelling in the lower extremities, and DVT is common among patients with  
17 stroke [32]. Our findings demonstrated that genetic variants of VTE and PE make a strong  
18 contribution to the risk of stroke. Moreover, weight change (weight gain) after depression is  
19 also a serious public health concern, and depressed individuals have a 58% chance of  
20 developing obesity [33]. Research conducted in 2021 revealed that patients who had a history  
21 of adolescent overweight and obesity as measured by BMI had a higher risk of developing an  
22 early-onset ischemic stroke [34]. Our study found the genetic variation of weight gain after  
23 depression may increase the risk of stroke. Our study highlights the genetic variants of the liver  
24 enzyme “gamma-glutamyl transferase” that were casually associated with stroke risk. Gamma-  
25 glutamyl transferase is a hepatic biomarker that is linked to liver dysfunction, physiology, and

1 metabolism [35]. Genetic variants associated with liver enzymes have previously been found  
2 to be genetically correlated with increased risk of cardiovascular diseases, and lipid and glucose  
3 metabolism [36]. The gamma-glutamyl transferase is secreted by the liver in response to  
4 various liver diseases[36], which could lead to increased metabolic disruption or lipid  
5 metabolism alterations ultimately contributing to stroke risk. Our study provides novel insights  
6 into the causal role of gamma-glutamyl transferase in the increased risk of stroke. Our study  
7 demonstrated that the blood cell trait i.e., platelet crit, was causally associated with stroke risk.  
8 Platelets are an essential component of blood and have an immense role in physiology. The  
9 total volume of platelets in the blood is regulated under normal physiological conditions. The  
10 total mass of platelets in the blood is called platelet crit. Platelet activation may narrow the  
11 blood vessels, obstructing the normal blood flow, which is called atherosclerosis [37].  
12 Atherosclerosis may increase the risk of stroke by impairing the circulation of blood through  
13 the blood vessels. Consistently, our ontology and pathway analysis also showed platelet  
14 activation and platelet coagulations were enriched in stroke and platelet crit traits.

15 Previous studies reported that lifestyle and vascular factors may increase the risk of ischemic  
16 and intracerebral haemorrhagic stroke by 80–90% [38]. MR studies revealed that genetically  
17 predicted type 2 diabetes was associated with ischemic heart disease, stroke, and cardiovascular  
18 diseases [39]. We found the use of medication GWAS (pioglitazone, insulin, gliclazide) for  
19 type 2 diabetes were causally associated with stroke risk. In these cases, type 2 diabetes would  
20 be the risk factor for stroke. Use of medication GWAS contribute to understand the aetiology  
21 and biological mechanisms of the lifestyle related risk factors [40]. It could be one of the  
22 explanations that power of these medication use GWAS were more robust than the disease  
23 associated GWAS (e.g., type 2 diabetes).

24 Further, gene-based association analyses revealed shared genetic architecture between stroke  
25 and causal traits. Gene based association analysis is an alternative and complementary to single

1 marker (SNPs), providing an opportunity to discover gene level associations for respective  
2 traits [41]. Therefore, in this study, we performed the gene-based associations analysis for  
3 stroke and causal traits. Our findings suggest many expected overlapped genes between stroke  
4 and causal traits. For instance, *ILF3* was found overlapping among stroke and deep venous  
5 thrombosis, blood clot in lung and leg, platelet crit, and pulmonary embolisms. *ILF3* is a protein  
6 coding gene, and its over expression was reported to be associated with the calcification of  
7 human aortic vascular smooth muscle cells and induced the formation of atherosclerotic  
8 plaques [42]. Likewise, we observed *ARMS2* was overlapped between stroke and deep venous  
9 thrombosis, platelet crit. *ARMS2* encodes the mitochondrial protein age-related maculopathy  
10 susceptibility protein 2 which was reported to be associated with oxidative damage, apoptosis,  
11 and aging process [43]. Furthermore, *OBFC1*, *SH3PXD2A*, *HCCAT5* were overlapped between  
12 stroke and atrial fibrillation, cardiac arrhythmias. Our previous study demonstrated  
13 *SH3PXD2A*, *OBFC1*, among others were causal risk biomarkers of stroke [44].

14 Our study demonstrated some important biological insights and molecular pathways enriched  
15 by the shared genes, providing novel insights into aetiology and underlying biological  
16 mechanisms implicated in the causal traits and stroke, including “oxidative damage”,  
17 “mitochondrial fatty acid beta-oxidation”, “platelet activation and aggregation”, “regulation of  
18 hemostasis”, “cell aging”, “fibrinolysis pathway”. The interruption of blood circulation in the  
19 brain is the hallmark of stroke, and have negatively impacted cell homeostasis, resulting in  
20 inflammation, oxidative damage, ionic imbalance, excitotoxicity, and ultimately induced  
21 neuronal cell death [45]. The production of high volume of intracellular molecules particularly,  
22  $\text{Ca}^{2+}$ ,  $\text{Na}^{+}$ , and adenosine diphosphate (ADP) causes oxidative stress that has a negative  
23 impact on mitochondrial function, as mitochondria are the fundamental energy generation  
24 stations of cells, ischemic stroke has a significant impact on them [46]. When necessary  
25 resources, particularly glucose, are inaccessible to brain cells, the mitochondria then produce

1 energy by consuming 15% more oxygen, produces more superoxides and less ATP via fatty  
2 acid oxidation ( $\beta$ -oxidation) process [47]. Our pathway-based enrichment analysis suggested  
3 the causal influence of mitochondrial fatty acid beta oxidation pathway in the progression of  
4 stroke. By inhibiting the mitochondrial fatty acid beta oxidation pathway could be a potential  
5 target for the treatment of stroke. Prior study has reported that oxidative stress is associated  
6 with aging process that influence the risk of stroke [48]. Another pathway, we found in our  
7 study is platelet activation and aggregation, platelet is the primary components of thrombi and  
8 have potential role in the formation of thrombus in both healthy and disease blood vessels. In  
9 hemostasis, during vascular injury, circulating platelet become struck in the injured site and  
10 stimulate the activation and aggression of hemostatic thrombi, which stop further bleeding.  
11 However, in thrombosis, abnormal platelet activation results in uncontrollable thrombus  
12 formation, which in turn may embolise or block the blood vessel, potentially resulting  
13 downstream ischemic events [49]. We also found fibrinolysis pathway which is involved in  
14 blood coagulation process and contributes to the progression of arterial and venous thrombosis  
15 [50] and ultimately induced the risk of stroke.

16 We acknowledged several limitations in this present study. Firstly, the GWAS summary  
17 statistics used in this study were obtained from the MEGASTROKE and UK Biobank cohort,  
18 where the participants are all from European ancestry. Thus, our findings should not be  
19 consistent with other ancestries unless they are verified using data from diverse populations.  
20 Secondly, our studies included 1504 traits, but other causal relationships may still exist with  
21 other traits. Thirdly, by definition, the LCV method evaluates the causal relationship between  
22 two traits and assumes no bidirectional causality [15]. Consequently, it is still debatable  
23 whether the LCV method would be able to determine the bidirectional causality between the  
24 traits. This assumption must be systematically evaluated in the future. Null findings in this  
25 study might be explained in a way that there is no causal association between the phenotypes

1 or there may exist bidirectional causality. In the current study, caution must be taken when  
2 interpreting null findings.

3 In summary, our study provides evidence for potential causal genetic relationships between  
4 stroke and other complex traits. Our findings suggest that the role of several cardiovascular  
5 traits (such as atrial fibrillation, cardiac arrhythmias), blood cell traits (such as platelet crits),  
6 and blood clot-related traits, and liver enzyme traits increase the risk of stroke. Our study also  
7 revealed the shared genetic architecture, genes, pathways implicated in stroke and causal traits.  
8 Overall, our findings support the evidence of previous epidemiological studies and provide  
9 novel insights into the causal genetic architecture, shared genes and pathways of complex traits  
10 and stroke, which in turn could be used as testable hypotheses to improve the development of  
11 future studies, treatments, and preventative strategies.

12

13

14

15

16

### 17 **Data Availability Statement**

18 All data here analysed is publicly available on MEGASTROKE consortium and the UK  
19 biobank summary data is available on CTG-VL.



## References

- [1] Organization, W.H. (2010). *World health statistics 2010*, World Health Organization.
- [2] Kuriakose, D. and Xiao, Z. (2020). Pathophysiology and treatment of stroke: present status and future perspectives. *International journal of molecular sciences*.
- [3] Boehme, A.K. et al. (2017). Stroke risk factors, genetics, and prevention. *Circulation research*.
- [4] Dichgans, M. (2007). Genetics of ischaemic stroke. *The Lancet Neurology*.
- [5] Bevan, S. et al. (2012). Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. *Stroke*.
- [6] Gretarsdottir, S. et al. (2008). Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. *Annals of neurology*.
- [7] Traylor, M. et al. (2012). Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. *The Lancet Neurology*.
- [8] Malik, R. et al. (2018). Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nature genetics*.
- [9] Malik, R. et al. (2018). Genome-wide meta-analysis identifies 3 novel loci associated with stroke. *Annals of neurology*.
- [10] Mishra, A. et al. (2022). Stroke genetics informs drug discovery and risk prediction across ancestries. *Nature*.
- [11] Georgakis, M.K. and Gill, D. (2021). Mendelian randomization studies in stroke: exploration of risk factors and drug targets with human genetic data. *Stroke*.
- [12] Liu, J. et al. (2018). Causal impact of type 2 diabetes mellitus on cerebral small vessel disease: a Mendelian randomization analysis. *Stroke*.
- [13] García-Marín, L.M. et al. (2021). Phenome-wide analysis highlights putative causal relationships between self-reported migraine and other complex traits. *The Journal of Headache and Pain*.
- [14] Siewert, K.M. et al. (2020). Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache. *International journal of epidemiology*.
- [15] O'Connor, L.J. and Price, A.L. (2018). Distinguishing genetic correlation from causation across 52 diseases and complex traits. *Nature genetics*.
- [16] Van Rheenen, W. et al. (2019). Genetic correlations of polygenic disease traits: from theory to practice. *Nature Reviews Genetics*.
- [17] Koellinger, P.D. and De Vlaming, R. (2019). Mendelian randomization: the challenge of unobserved environmental confounds. *International journal of epidemiology*.
- [18] Malik, R. et al. (2018). Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nature genetics*.
- [19] Cuellar-Partida, G. et al. (2019). Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses. *BioRxiv*.
- [20] Bulik-Sullivan, B.K. et al. (2015). LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature genetics*.
- [21] Haworth, S. et al. (2021). Assessment and visualization of phenome-wide causal relationships using genetic data: an application to dental caries and periodontitis. *European Journal of Human Genetics*.

- [22] Davey Smith, G. and Ebrahim, S. (2003). 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *International journal of epidemiology*.
- [23] Zhu, Z. et al. (2018). Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nature communications*.
- [24] Bakshi, A. et al. (2016). Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits. *Scientific reports*.
- [25] Kamburov, A. et al. (2013). The ConsensusPathDB interaction database: 2013 update. *Nucleic acids research*.
- [26] Kamel, H. et al. (2016). Atrial fibrillation and mechanisms of stroke: time for a new model. *Stroke*.
- [27] Santos, J.V. et al. (2017). Atrial fibrillation as an ischemic stroke clinical and economic burden modifier: a 15-year nationwide study. *Value in Health*.
- [28] Son, M.K. et al. (2017). Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort. *PloS one*.
- [29] Kamel, H. et al. (2016). Atrial fibrillation and mechanisms of stroke: time for a new model. *Stroke*.
- [30] Heit, J.A. (2005). Venous thromboembolism: disease burden, outcomes and risk factors. *Journal of Thrombosis and Haemostasis*.
- [31] Glynn, R.J. and Rosner, B. (2005). Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. *American journal of epidemiology*.
- [32] Liu, Z. et al. (2021). Incidence and Risk Factors of Lower-Extremity Deep Vein Thrombosis After Thrombolysis Among Patients with Acute Ischemic Stroke. *Pharmacogenomics and Personalized Medicine*.
- [33] Blasco, B.V. et al. (2020). Obesity and depression: Its prevalence and influence as a prognostic factor: A systematic review. *Psychiatry investigation*.
- [34] Bardugo, A. et al. (2021). Body mass index in 1.9 million adolescents and stroke in young adulthood. *Stroke*.
- [35] Pazoki, R. et al. (2021). Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. *Nature communications*.
- [36] Pazoki, R. et al. (2021). Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. *Nature communications*.
- [37] Mohamed, A.-A.B. et al. (2019). The mean platelet volume and plateletcrit as predictors of short-term outcome of acute ischemic stroke. *The Egyptian journal of neurology, psychiatry and neurosurgery*.
- [38] Hauer, A.J. et al. (2017). Age-Specific vascular risk factor profiles according to stroke subtype. *Journal of the American Heart Association*.
- [39] Huang, M. et al. (2022). Causal Association of Type 2 diabetes mellitus and glycemic traits with cardiovascular diseases and lipid traits: a Mendelian randomization study. *Frontiers in Endocrinology*.
- [40] Wu, Y. et al. (2019). Genome-wide association study of medication-use and associated disease in the UK Biobank. *Nature communications*.
- [41] Bakshi, A. et al. (2016). Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits. *Scientific reports*.
- [42] Xie, F. et al. (2021). ILF3 is responsible for hyperlipidemia-induced arteriosclerotic calcification by mediating BMP2 and STAT1 transcription. *Journal of Molecular and Cellular Cardiology*.

- [43] Zhang, J. et al. (2021). Meta-analysis of the pharmacogenetics of ARMS2 A69S polymorphism and the response to advanced age-related macular degeneration. *Ophthalmic research*.
- [44] Islam, T. et al. (2023). Integration of Mendelian randomisation and systems biology models to identify novel blood-based biomarkers for stroke. *Journal of Biomedical Informatics*.
- [45] Doyle, K.P. et al. (2008). Mechanisms of ischemic brain damage. *Neuropharmacology*.
- [46] Mavroudakos, L. and Lanekoff, I. (2023). Ischemic Stroke Causes Disruptions in the Carnitine Shuttle System. *Metabolites*.
- [47] Schönfeld, P. and Reiser, G. (2013). Why does brain metabolism not favor burning of fatty acids to provide energy?-Reflections on disadvantages of the use of free fatty acids as fuel for brain. *Journal of Cerebral Blood Flow & Metabolism*.
- [48] Islam, T. et al. (2023). Integration of Mendelian randomisation and systems biology models to identify novel blood-based biomarkers for stroke. *Journal of Biomedical Informatics*.
- [49] Rana, A. et al. (2019). Shear-dependent platelet aggregation: mechanisms and therapeutic opportunities. *Frontiers in cardiovascular medicine*.
- [50] Grover, S.P. and Mackman, N. (2019). Intrinsic pathway of coagulation and thrombosis: Insights from animal models. *Arteriosclerosis, thrombosis, and vascular biology*.

## **Acknowledgments**

We thank the MEGASTROKE project for making stroke GWAS summary statistics data publicly available. The author list of MEGASTROKE is available in Supplementary Table 23.

T.I. is supported by a Research Training scholarship from The University of Queensland, Australia.

**Author contributions:** All authors contributed to the design and conception of the study. T.I collected datasets and performed the analyses supervised by M.A.M. L.M.G provided important insights into the interpretation of the results. TI wrote the manuscript and all authors commented on the manuscript. All authors read and approved the final manuscript. T.I is a recipient of an RTP scholarship from the University of Queensland, Australia.

**Competing Interests:** “Authors declare no competing of interest”.

## Figure legends:

**Figure 1.** The schematic diagram illustrates the genetic relationships between 1504 complex traits and stroke. The genetic correlation was consistent across the phenotypes, demonstrating that genetic variants specific to each of the 1504 complex traits had consistent positive or negative correlations with the genetic variants associated with stroke. Gene-based and pathway-based analyses revealed shared genetic architecture and molecular mechanisms shared between causal traits and stroke. This figure was generated from Biorender.com.

**Figure 2.** Share genes between causal traits and stroke. Right side represents causal traits and stroke, and left side represents shared genes between causal traits and stroke.

**Figure 3.** Common pathways shared between complex traits and stroke. (A) pathways shared between atrial fibrillation, atrial fibrillation and flutter, and cardiac arrhythmias and stroke; (B) pathways shared between blood clot in lung, blood clot in leg, deep venous thrombosis, pulmonary embolisms, and stroke; (C) pathways shared between platelet crit and stroke; (D) pathways shared between gamma glutamyl-transferase and stroke.

**Figure 4.** Common gene ontology (GO) terms shared between complex traits and stroke. (A) shared GO term between pulmonary embolisms and stroke; (B) common GO term between deep venous thrombosis and stroke; (C) shared GO between blood clot in lung and stroke; (D) shared GO term between blood clot in leg and stroke; (E) shared GO between platelet crit and stroke; (F) shared GO term between gamma-glutamyl transferase and stroke.

Table legends:

**Table 1.** Traits with potential causal association with stroke. This table represents the phenotypes with  $FDR < .05$  and robust genetic causal proportions ( $|GCP| > 0.60$ ) with stroke.

**Table 2.** Traits with potential causal association with stroke using generalised Mendelian randomisation analysis.

**Table 1.** Traits with potential causal association with stroke. This table represents the phenotypes with  $FDR < .05$  and robust genetic causal proportions ( $|GCP| > 0.60$ ) with stroke.

Trait	GCP	GCPse	GCPpval	rG	rGse	rGpval
Self-reported atrial fibrillation	-0.97	0.03	$8.97 \times 10^{-202}$	0.58	0.18	$9.51 \times 10^{-4}$
Self-reported pulmonary embolism	-0.79	0.15	$1.37 \times 10^{-7}$	0.45	0.13	$3.20 \times 10^{-4}$
Blood clot in the lung diagnosed by a doctor	-0.75	0.17	$2.46 \times 10^{-5}$	0.44	0.13	$3.41 \times 10^{-4}$
Cardiac arrhythmias	-0.72	0.19	$2.99 \times 10^{-4}$	0.44	0.08	$1.76 \times 10^{-7}$
Blood clot in the leg diagnosed by a doctor	-0.74	0.18	$5.25 \times 10^{-5}$	0.43	0.11	$1.96 \times 10^{-4}$
Medication: Gliclazide	-0.66	0.23	$3.75 \times 10^{-3}$	0.42	0.09	$2.33 \times 10^{-5}$
Self-reported deep venous thrombosis	-0.74	0.18	$4.23 \times 10^{-5}$	0.40	0.11	$2.60 \times 10^{-4}$
Atrial fibrillation and flutter (ICD10)	-0.80	0.14	$2.10 \times 10^{-8}$	0.40	0.08	$1.91 \times 10^{-6}$
Medication: Insulin	-0.84	0.12	$1.43 \times 10^{-11}$	0.38	0.14	$6.43 \times 10^{-3}$
Medication: Pioglitazone	-0.74	0.17	$1.72 \times 10^{-5}$	0.33	0.12	$8.45 \times 10^{-3}$
Weight change during worst episode of depression: Gained weight	-0.64	0.23	$4.03 \times 10^{-3}$	0.32	0.12	$1.01 \times 10^{-2}$
Deep venous thrombosis of lower extremities and pulmonary embolism	-0.78	0.14	$1.28 \times 10^{-8}$	0.24	0.08	$6.00 \times 10^{-3}$
Gamma glutamyltransferase (female)	-0.69	0.15	$4.13 \times 10^{-6}$	0.16	0.04	$3.23 \times 10^{-4}$
Platelet crit	-0.67	0.20	$7.61 \times 10^{-4}$	0.14	0.04	$1.32 \times 10^{-3}$
Gamma glutamyltransferase (male)	-0.64	0.19	$7.61 \times 10^{-4}$	0.14	0.05	$6.60 \times 10^{-3}$

This table represents the traits with significant false discovery rate ( $FDR < .05$ ); GCP: genetic causal proportion; GCP se: genetic causal proportion standard deviation; GCP pval: genetic causal proportion unadjusted p-value; rG: genetic correlation; rG se: genetic correlation standard deviation; rG pval: genetic correlation unadjusted p-value.

**Table 2.** Traits with potential causal association with stroke using Generalised Mendelian Randomisation analysis.

<b>Exposure</b>	<b>Outcome</b>	<b>Effect</b>	<b>SE</b>	<b><i>P</i></b>	<b>HEIDI test <i>P</i></b>	<b>SNPs #</b>
Self-reported atrial fibrillation	Stroke	13.80	1.37	$1.2 \times 10^{-23}$	0.28	13
Self-reported pulmonary embolism		20.06	2.75	$3.2 \times 10^{-13}$	0.31	4
Blood clot in the lung diagnosed by a doctor		17.20	2.69	$1.6 \times 10^{-10}$	0.12	3
Cardiac arrhythmias		7.00	0.65	$1.4 \times 10^{-26}$	0.06	24
Blood clot in the leg diagnosed by a doctor		4.72	1.13	$2.9 \times 10^{-5}$	0.1	9
Medication: Gliclazide		5.23	2.22	0.01	0.08	7
Self-reported deep venous thrombosis		4.75	1.14	$3.2 \times 10^{-5}$	0.09	9
Atrial fibrillation and flutter (ICD10)		7.40	0.66	$6.1 \times 10^{-29}$	0.12	29
Medication: Insulin		1.89	0.89	0.02	0.2	10
Deep venous thrombosis of lower extremities and pulmonary embolism		15.21	2.18	$3.49 \times 10^{-12}$	0.26	5
Gamma glutamyltransferase		0.07	0.01	$8.23 \times 10^{-7}$	0.05	654
Platelet crit		1.72	0.37	$4.71 \times 10^{-6}$	0.06	616

This table represents the traits with significant false discovery rate (FDR < .05); SE: standard error; *P*: *p*-value; HEIDI test *P*: heterogeneity in dependent instruments test. SNPs#: number of single nucleotide polymorphism



Figure 1.






Figure 3.




Figure 4.

